Novartis is a Swiss multinational pharmaceutical company headquartered in Basel and formed in 1996 through the merger of Ciba-Geigy and Sandoz. The company focuses on innovative medicines and is listed on the SIX Swiss Exchange under NOVN.
Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604571 |
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07604324 |
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07598448 |
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain |
NOT_YET_RECRUITING | |
| NCT07598422 |
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome |
NOT_YET_RECRUITING | |
| NCT07594587 |
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease |
NOT_YET_RECRUITING | |
| NCT07587723 |
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag |
NOT_YET_RECRUITING | |
| NCT07570979 |
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer |
RECRUITING | PHASE1 |
| NCT07570966 |
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07566988 |
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients |
COMPLETED | |
| NCT07564401 |
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy |
RECRUITING | PHASE1/PHASE2 |
